KALARIS THERAPEUTICS, INC. (KLRS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -47.76M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 32.87M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-47.76M | (m) | (m) | $32.87M | (m) | (m) |
| 2026-03-31 | $-47.63M | (m) | (m) | $32.30M | (m) | (m) |
| 2025-12-31 | $-46.15M | (m) | (m) | $30.75M | (m) | (m) |
| 2025-09-30 | $-56.19M | (m) | (m) | $-5.26M | (m) | (m) |
| 2025-06-30 | $-81.30M | (m) | (m) | $21.64M | (m) | (m) |
| 2025-03-31 | $-73.23M | (m) | (m) | $16.41M | (m) | (m) |
| 2024-12-31 | $-65.44M | (m) | (m) | $12.34M | (m) | (m) |
| 2024-09-30 | $-108.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-149.44M | (m) | (m) | $79.79M | (m) | (m) |
| 2024-03-31 | $-188.97M | (m) | (m) | $114.53M | (m) | (m) |
| 2023-12-31 | $-199.90M | (m) | (m) | $133.07M | (m) | (m) |
| 2023-09-30 | $-177.93M | (m) | (m) | $128.12M | (m) | (m) |
| 2023-06-30 | $-173.92M | (m) | (m) | $123.97M | (m) | (m) |
| 2023-03-31 | $-171.24M | (m) | (m) | $120.52M | (m) | (m) |
| 2022-12-31 | $-171.20M | (m) | (m) | $118.87M | (m) | (m) |
| 2022-09-30 | $-186.56M | (m) | (m) | $132.05M | (m) | (m) |
| 2022-06-30 | $-189.12M | (m) | (m) | $135.11M | (m) | (m) |
| 2022-03-31 | $-182.15M | (m) | (m) | $129.41M | (m) | (m) |
| 2021-12-31 | $-169.82M | (m) | (m) | $120.73M | (m) | (m) |
| 2021-09-30 | $-139.44M | (m) | (m) | $95.89M | (m) | (m) |
| 2021-06-30 | $-117.83M | (m) | (m) | $80.01M | (m) | (m) |
| 2021-03-31 | $-92.33M | (m) | (m) | $63.22M | (m) | (m) |
| 2020-12-31 | $-71.31M | (m) | (m) | $49.66M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-26.70M | $165.00K | (m) | $16.25M | (m) | -16182.42% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |